CUREVAC NV revenue breakdown overview

CUREVAC NV revenue for the last year amounted to 50.00 M CHF, the most of which — 48.93 M CHF — came from its highest performing source at the moment, Transformative Medicines Based on Messenger Ribonucleic Acid, the year earlier bringing 65.52 M CHF. The greatest contribution to the revenue figure was made by Belgium — last year it brought CUREVAC NV 42.90 M CHF, and the year before that — 60.51 M CHF.